---
title: "Laekna’s Breast Cancer Drug LAE002 Hits Phase III PFS Goal, NDA in China Planned"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/282760815.md"
description: "Laekna, Inc. (HK:2105) announced positive results from its Phase III AFFIRM-205 trial for LAE002 (afuresertib) in breast cancer patients, achieving a median progression-free survival of 7.6 months. The company plans to submit a new drug application in China and is seeking global partnerships. Laekna could receive up to RMB2.045 billion in payments under its China licensing deal. Analysts rate the stock as a Buy with a price target of HK$24.16. Laekna focuses on innovative oncology therapies, particularly for patients with specific genetic alterations in breast cancer."
datetime: "2026-04-15T00:37:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/282760815.md)
  - [en](https://longbridge.com/en/news/282760815.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/282760815.md)
---

# Laekna’s Breast Cancer Drug LAE002 Hits Phase III PFS Goal, NDA in China Planned

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

The latest update is out from Laekna, Inc. ( (HK:2105) ).

Laekna reported positive topline results from its Phase III AFFIRM-205 trial of LAE002 (afuresertib) plus fulvestrant in patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer harboring PIK3CA, AKT1 or PTEN alterations. The combination achieved a median progression-free survival of 7.6 months versus 2.0 months for placebo plus fulvestrant, with a hazard ratio of 0.33 and a favorable safety profile marked by low discontinuation rates.

The company plans to work with its China partner Qilu Pharmaceutical to submit a new drug application to China’s National Medical Products Administration in the near term and is seeking ex-China partnerships to accelerate global development and commercialization. Under an existing exclusive China licensing deal, Laekna is eligible for up to RMB2.045 billion in upfront and milestone payments plus tiered royalties, positioning LAE002 as a potentially important new targeted option in a large molecularly defined breast cancer segment if ultimately approved.

The most recent analyst rating on (HK:2105) stock is a Buy with a HK$24.16 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.

**More about Laekna, Inc.**

Laekna, Inc. is a Cayman Islands–incorporated biopharmaceutical company listed in Hong Kong that focuses on developing innovative oncology therapies. Its lead candidate LAE002 (afuresertib) is a potent pan-AKT inhibitor in late-stage development for breast and prostate cancer, targeting patients with PIK3CA, AKT1 and PTEN alterations, which are present in about half of breast cancer cases.

**Average Trading Volume:** 2,608,066

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** HK$7.53B

For a thorough assessment of 2105 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [02105.HK](https://longbridge.com/en/quote/02105.HK.md)

## Related News & Research

- [Bank of America Securities Reaffirms Their Buy Rating on Laekna, Inc. (2105)](https://longbridge.com/en/news/285640720.md)
- [CICC Sticks to Their Buy Rating for Laekna, Inc. (2105)](https://longbridge.com/en/news/283298518.md)
- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)
- [EXCLUSIVE-FDA drug center head expected to leave after commissioner's exit, sources say](https://longbridge.com/en/news/286589761.md)
- [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md)